Clinical trials: Blood Pressure, High
Primary Open Angle Glaucoma, Open Angle Glaucoma
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
The goal of this clinical trial is to show non-inferiority of the MIMS® device/procedure with Mitomycin-C, in terms of its surgical success rate, compared to trabeculectomy with Mitomycin-C in subjects diagnosed with primary open…
- Trial name
- NCT06313749
- Testing
- Minimally Invasive Micro Sclerostomy Device
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- Sanoculis Ltd
Pulmonary Arterial Hypertension
Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension
The development of selexipag for intravenous administration will be useful to avoid treatment interruptions in patients with pulmonary arterial hypertension (PAH) already treated with selexipag administered orally as tablets…
- Trial name
- NCT03187678
- Testing
- i.v. selexipag, oral selexipag (Uptravi)
- Where
- 8 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- Actelion
Primary Open Angle Glaucoma, Ocular Hypertension
Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension
This randomized dose-ranging study will evaluate the safety, tolerability, and preliminary efficacy (reduction in intraocular pressure) of multiple dose levels of ATS907, vehicle, or latanoprost in subjects with primary open…
- Trial name
- NCT01520116
- Testing
- Stage 1 - ATS907 - Dose 1, Stage 1 - ATS907 - Dose 2, Stage 1 - ATS907 - Dose 3
- Where
- 5 sites in United States
- Volunteers
- 180 people
- Sponsor
- Altheos, Inc.
Essential Hypertension
Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine
This study will assess whether LCZ696 when used in combination with amlodipine will provide greater BP lowering benefit compared to amlodipine alone in Asian hypertensive patients not adequately responsive to amlodipine therapy.
- Trial name
- NCT01663233
- Testing
- LCZ696, Amlodipine
- Where
- 28 sites in China, Japan and 4 more
- Volunteers
- 266 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Vascular Diseases
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent.
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases
- Trial name
- RADIANCE-II (NCT03614260)
- Testing
- Paradise Renal Denervation System, Renal Angiogram
- Where
- 47 sites in United States, Belgium and 6 more
- Volunteers
- 224 people
- Sponsor
- ReCor Medical, Inc.
Hypertension
TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial
The purpose of this study is to determine the effectiveness of candesartan cilexetil in preventing hypertension in people with high normal blood pressure.
- Trial name
- NCT00227318
- Testing
- ATACAND
- Where
- 42 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Open-angle Glaucoma, Ocular Hypertension
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study
- Trial name
- NCT06267274
- Testing
- Bimatoprost Ophthalmic Solution, 0.01%, LUMIGAN® (bimatoprost ophthalmic solution) 0.01%
- Where
- 4 sites in United States
- Volunteers
- 240 people
- Sponsor
- Amneal Pharmaceuticals, LLC
Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2
- Trial name
- Re-PHIRE (NCT05737940)
- Testing
- AZD3427
- Where
- 60 sites in United States, Austria and 12 more
- Volunteers
- 260 people
- Sponsor
- AstraZeneca
Refractive Error, Glaucoma
A Post-market Clinical Study to Collect Safety and Performance Data on Johnson & Johnson Surgical Vision Products
Retrospective collection of data from medical records, multicenter, post-market clinical follow-up study.
- Conditions
- Refractive Error, Glaucoma, Cataracts, Clear Lens Exchange
- Trial name
- NCT05394324
- Testing
- Intervention
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 1,674 people
- Sponsor
- Johnson & Johnson Surgical Vision, Inc.
Hypertension, Hyperhomocysteinemia
CSPPT- Chronic Kidney Diseases Study
The purpose of this trial is to confirm that enalapril maleate and folic acid tablets is more effective in preventing renal function decline among the patients with primary hypertension when compared to enalapril maleate.
- Trial name
- CSPPT-CKD (NCT01871740)
- Testing
- Enalapril maleate and folic acid tablets, Enalapril maleate
- Where
- 2 sites in China
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Essential Hypertension, Healthy Volunteers
Phase 1 Clinical Study of MWX401 Injection in Chinese Healthy Participants and Participants With Mild Hypertension
This is a single-center, randomized, double-blind, placebo-controlled, single ascending-dose phase 1 clinical study, aimed at evaluating the safety, tolerability, PK, PD and immunogenicity of single subcutaneous administration of…
- Trial name
- NCT07803835
- Testing
- MWX401 1, MWX401 2, MWX401 3
- Where
- China
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Hypertension, Chronic Kidney Disease
Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age
The purpose of this study is to assess the long-term safety and tolerability profile of valsartan and valsartan-based treatments in children with hypertension, with or without chronic kidney disease.
- Trial name
- NCT01365481
- Testing
- Valsartan, amlodipine, Hydrochlorothiazide
- Where
- 28 sites in Colombia, Finland and 8 more
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy
A multi-center, randomized, double-blind, phase IV clinical trial to compare the efficacy and safety of OROSARTAN® tablet 5/160mg versus CODIOVAN® tablet 160/12.5mg in patients with essential hypertension uncontrolled with…
- Trial name
- NCT02433119
- Testing
- OROSARTAN® 5/160mg, CODIOVAN® 160/12.5mg
- Where
- South Korea
- Volunteers
- 238 people
- Sponsor
- Dong-A ST Co., Ltd.
Glaucoma
Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost
Evaluate the relative efficacy and tolerability of Alphagan P compared to Trusopt as adjunctive therapy
- Trial name
- NCT00348400
- Testing
- Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost
- Where
- United States
- Sponsor
- Innovative Medical
Hypertension
Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population
To analyse the control rate of irbesartan/hydrochlorothiazide(HCTZ) (COAPROVEL) in the treatment of patients with mild to moderate primary hypertension.
- Trial name
- NCT00847834
- Testing
- Irbesartan 150mg / Hydrochlorothiazide 12.5mg, Irbesartan 150mg
- Where
- China
- Volunteers
- 968 people
- Sponsor
- Sanofi
Glaucoma, Open-Angle, Glaucoma
iStent Inject New Enrollment Post-Approval Study
Study to evaluate the rate of clinically relevant complications associated with iStent inject placement in the post-market setting.
- Trial name
- NCT04624698
- Testing
- iStent Inject Implantation
- Where
- 3 sites in United States
- Volunteers
- 358 people
- Sponsor
- Glaukos Corporation
Heart Failure, Acute Myocardial Infarction
Eplerenone in Heart Failure Treatment
Beta-blockers should be administered to all patients with heart failure stage II to IV according to NYHA.Beta-blockers reduce mortality and hospitalizations and improve the operational phase for all categories of patients with…
- Conditions
- Heart Failure, Acute Myocardial Infarction, Hypertension
- Trial name
- INOSET (NCT02344199)
- Where
- 3 sites in Greece
- Volunteers
- 450 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Open Angle Glaucoma, Ocular Hypertension
SYL040012, Treatment for Open Angle Glaucoma
The purpose of this double-masked, randomized, controlled study is to assess the safety and ocular hypotensive efficacy of four different doses of SYL040012 (bamosiran) eye drops compared to Timolol maleate 0.5% after 28…
- Trial name
- SYLTAG (NCT02250612)
- Testing
- 1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), 1 drop of 1.125% SYL040012 (bamosiran)
- Where
- 21 sites in United States, Estonia and 2 more
- Volunteers
- 184 people
- Sponsor
- Sylentis, S.A.
Glaucoma, Neovascular
Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied
The researchers in this trial want to learn how the drug aflibercept works in in Japanese patients with increased eye pressure that is caused by new blood vessels growing in the eye (neovascular glaucoma or NVG).
- Trial name
- VENERA (NCT03639675)
- Testing
- Aflibercept (EYLEA, BAY86-5321), Topical IOP-lowering drugs
- Where
- 7 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Bayer
Ocular Hypertension, Glaucoma
A Study of Glaucoma or Ocular Hypertension in Patients Within the United States
Safety and efficacy study comparing between fixed combination latanoprost-timolol and its component parts.
- Trial name
- NCT00800267
- Testing
- latanoprost 0.005%, fixed combination latanoprost-timolol, timolol 0.5%
- Where
- 53 sites in United States
- Volunteers
- 418 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.